AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06327243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic tape ( kinesio tape)
Description: This group will receive the tape on their quadriceps femoris muscle. First, the tape will be cut in a Y-shaped Kinesio type and then applied over the quadriceps femoris muscle. The tape will be applied at a point of 5 cm inferior to the anterior superior iliac spine to the patella (origin to insertion), with the patient in a supine position with 25% tension on the tape. Then, each patient will flex his or her knee, and the Y-shaped tape (the end of the tape) will be circled around the patella, ending at its inferior side with no tension.
Study NCT06327243 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: Sham taping will be applied horizontally across the muscle fibers without any stretching. the tape here will be applied transverse to the quadriceps femoris muscle. The patients will be in a supine position with their hips flexed at 30 degrees and their knees flexed at 60 degrees.
Study NCT06180512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine high dose
Description: 4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
Study NCT06180512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine low dose
Description: 4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
Study NCT06180512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
Study NCT05901922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training
Description: In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
Study NCT05309941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Cues Nutrition Messaging
Description: Participants will view a 5 minute nutrition education video focused on intuitive eating principles.
Study NCT05309941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Cues Nutrition Messaging
Description: Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.
Study NCT04657770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
Study NCT05177588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 2000 mg/day
Study NCT05908266 — intervention group
Intervention type: OTHER
Intervention: Reaching movements
Description: Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
Study NCT05908266 — intervention group
Intervention type: OTHER
Intervention: Disease Assessment
Description: Disease stage assessed by trained professionals
Study NCT04915534 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu® AuraGain™ Laryngeal Mask (LM)
Description: Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.
Study NCT05158400 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound examination on the hand
Study NCT05499520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Anti-Smoking Messages
Description: Anti-smoking messages will be administered online via a Qualtrics survey.
Study NCT04476329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib 40 MG
Description: Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor \[VEGFR\] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 \[TIE2\]), stem cell growth factor receptor (KIT, rearranged during transfection \[RET\], p38-alpha, a member of the mitogen activated protein kinase \[MAPK\] family, proto-oncogene c-RAF \[c-RAF\], proto-oncogene BRAF \[BRAF\], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor \[PDGFR\], fibroblast growth factor receptor1 \[FGFR1\]) and tumor immunity (colony stimulating factor 1 receptor \[CSF1R\]).
Study NCT05565664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride will be made in a 20 ml syringe in a concentration of 1.25 mg/ml. Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication.
Study NCT05565664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: A 20 ml syringe will contain magnesium sulphate in a concentration 100 mg/ml (10%). Patients will receive 40 mg/kg of IV magnesium sulphate (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication.
Study NCT04840264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25 mg/square metre, D1, D8, D15, repeat every 4 weeks.
Study NCT06428890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: dietary supplements that rich in polyphenolic compounds
Study NCT06428890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape Seed Extract
Description: dietary supplements that rich in polyphenolic compounds
Study NCT06428890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Starch
Study NCT06428890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch
Study NCT05825066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study NCT05825066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study NCT05825066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiological Assessments
Description: CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.
Study NCT05825066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study NCT04840264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/msquare metre, D1, D15, repeat every 4 weeks.
Study NCT04840264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
Study NCT05336708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Group
Description: In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
Study NCT05336708 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupressure Group
Description: In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study NCT05101044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavioral Therapy (ABBT) Intervention
Description: This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
Study NCT04793347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock master (shock waves device)
Description: device produces shock waves
Study NCT05503745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT-F+MIT
Description: The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
Study NCT05503745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
Study NCT05917431 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT plus tislelizumab and regorafenib
Description: Participants will receive SBRT plus tislelizumab and regorafenib concurrently
Study NCT05272345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sexual therapy
Description: In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
Study NCT06154967 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tereotactic body radiotherapy
Description: In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
Study NCT06108102 — intervention group
Intervention type: OTHER
Intervention: Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)
Description: Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
Study NCT06550167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nano-PSO, Pomegranate seed oil (omega-5)
Description: During the intervention, Nano-PSO dietary supplement will be administered to the participants in the assigned group.~Participants will be followed before and after treatment to assess the effects of Nano-PSO on cognitive status, serum concentrations of trophic factors, and other relevant parameters . This randomized, double-blind, controlled clinical trial design allows for a rigorous evaluation of the potential benefits of Nano-PSO in patients with substance use disorders. The study aims to provide valuable insights into the neuroprotective and cognitive-enhancing properties of Nano-PSO in this population.
Study NCT06550167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In this arm of the study the participants will receive a placebo as a control treatment . The placebo is essential in clinical trials to compare the effects of the active intervention (Nano-PSO) with those of an inert substance.
Study NCT04830098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises
Description: It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
Study NCT04830098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Description: It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
Study NCT04992858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: CT053PTSA will be administered orally once a day
Study NCT04451213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI head
Description: MRI head
Study NCT05373069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ischemic preconditioning of diep-type flap
Description: Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization.
Study NCT04672954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
Study NCT04672954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 milligram (mg) BI 474121
Description: 2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
Study NCT04672954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 milligram (mg) BI 474121
Description: 10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
Study NCT04672954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 milligram (mg) BI 474121
Description: 20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
Study NCT04672954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 milligram (mg) BI 474121
Description: 40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
Study NCT05624047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding education using hybrid simulation method
Description: In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
Study NCT05624047 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine verbal breastfeeding education
Description: Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
Study NCT05624047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine verbal breastfeeding education
Description: Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
Study NCT04708171 — intervention group
Intervention type: PROCEDURE
Intervention: Awake mapping under local anesthesia
Description: During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
Study NCT04708171 — intervention group
Intervention type: PROCEDURE
Intervention: Asleep mapping under general anesthesia
Description: During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
Study NCT04708171 — intervention group
Intervention type: PROCEDURE
Intervention: Resection under general anesthesia without mapping
Description: During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
Study NCT05099094 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD311
Description: Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
Study NCT05045937 — intervention group
Intervention type: DRUG
Intervention: Ivermectin
Description: Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
Study NCT05210504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Lysine
Description: 5g L-lysine in 50ml water, administered orally
Study NCT05210504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal (0.9%) Saline
Study NCT04583709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Belt
Description: ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording
Study NCT04348968 — intervention group
Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol.
Study NCT04858178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic inhibition
Description: Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.